225 related articles for article (PubMed ID: 32311967)
21. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Raje N; Berdeja J; Lin Y; Siegel D; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Turka A; Lam LP; Morgan RA; Friedman K; Massaro M; Wang J; Russotti G; Yang Z; Campbell T; Hege K; Petrocca F; Quigley MT; Munshi N; Kochenderfer JN
N Engl J Med; 2019 May; 380(18):1726-1737. PubMed ID: 31042825
[TBL] [Abstract][Full Text] [Related]
22. PRESUMPTIVE RECURRENCE OF INTRAOCULAR LYMPHOMA DESPITE CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY.
Taher A; Abadir E; McCluskey P; Hamad N; Lo TH; Heydon P
Retin Cases Brief Rep; 2023 Sep; 17(5):562-566. PubMed ID: 37643043
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma.
Rejeski K; Jain MD; Smith EL
Transplant Cell Ther; 2023 Jul; 29(7):418-428. PubMed ID: 37076102
[TBL] [Abstract][Full Text] [Related]
24. Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma.
Xu J; Wang Q; Xu H; Gu C; Jiang L; Wang J; Wang D; Xu B; Mao X; Wang J; Wang Z; Xiao Y; Zhang Y; Li C; Zhou J
J Hematol Oncol; 2018 Oct; 11(1):128. PubMed ID: 30348186
[TBL] [Abstract][Full Text] [Related]
25. [Chimeric antigen receptor T-cell therapy for multiple myeloma].
Hosen N
Rinsho Ketsueki; 2021; 62(6):619-623. PubMed ID: 34219089
[TBL] [Abstract][Full Text] [Related]
26. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
Munshi PN; Ujjani C
Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
[TBL] [Abstract][Full Text] [Related]
27. Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: A case study with anti-BCMA CAR-T.
Singh AP; Chen W; Zheng X; Mody H; Carpenter TJ; Zong A; Heald DL
CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):362-376. PubMed ID: 33565700
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
Front Immunol; 2021; 12():720571. PubMed ID: 34421924
[TBL] [Abstract][Full Text] [Related]
29. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies.
Walti CS; Krantz EM; Maalouf J; Boonyaratanakornkit J; Keane-Candib J; Joncas-Schronce L; Stevens-Ayers T; Dasgupta S; Taylor JJ; Hirayama AV; Bar M; Gardner RA; Cowan AJ; Green DJ; Boeckh MJ; Maloney DG; Turtle CJ; Hill JA
JCI Insight; 2021 Jun; 6(11):. PubMed ID: 33914708
[TBL] [Abstract][Full Text] [Related]
30. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
Ali SA; Shi V; Maric I; Wang M; Stroncek DF; Rose JJ; Brudno JN; Stetler-Stevenson M; Feldman SA; Hansen BG; Fellowes VS; Hakim FT; Gress RE; Kochenderfer JN
Blood; 2016 Sep; 128(13):1688-700. PubMed ID: 27412889
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy with cells.
Chong EA; Porter DL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):590-597. PubMed ID: 33275723
[TBL] [Abstract][Full Text] [Related]
32. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
33. [Chimeric antigen receptor T-cell therapy for multiple myeloma].
Hosen N
Rinsho Ketsueki; 2018; 59(10):2189-2194. PubMed ID: 30305525
[TBL] [Abstract][Full Text] [Related]
34. CAR T-cell therapy for multiple myeloma: state of the art and prospects.
van de Donk NWCJ; Usmani SZ; Yong K
Lancet Haematol; 2021 Jun; 8(6):e446-e461. PubMed ID: 34048683
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients.
Sharma A; Singh V; Deol A
Transplant Cell Ther; 2023 Feb; 29(2):108.e1-108.e7. PubMed ID: 36371048
[TBL] [Abstract][Full Text] [Related]
37. Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function.
He SL; Cheng YH; Wang D; Xu ML; Que YM; Xu YJ; Ma LM; Li CR; Zhou JF
Curr Med Sci; 2021 Jun; 41(3):474-481. PubMed ID: 34169427
[TBL] [Abstract][Full Text] [Related]
38. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
[TBL] [Abstract][Full Text] [Related]
39. Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T.
Nerreter T; Letschert S; Götz R; Doose S; Danhof S; Einsele H; Sauer M; Hudecek M
Nat Commun; 2019 Jul; 10(1):3137. PubMed ID: 31316055
[TBL] [Abstract][Full Text] [Related]
40. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
Salaroli A; Spilleboudt C; Bron D; Lewalle P
Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]